## Bone morphogenetic protein 2 exerts diverse effects on expressed in human pancreatic cancer in vivo

Gastroenterology 116, 1202-1216 DOI: 10.1016/s0016-5085(99)70024-7

**Citation Report** 

#	Article	IF	CITATIONS
1	Molecular Aspects of Pancreatic Cancer and Future Perspectives. Digestive Surgery, 1999, 16, 281-290.	0.6	77
2	Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Digestive Diseases and Sciences, 1999, 44, 1793-1802.	1.1	29
3	Identification of differentially expressed genes in nasopharyngeal carcinoma by means of the Atlas human cancer cDNA expression array. Journal of Cancer Research and Clinical Oncology, 2000, 126, 400-406.	1.2	40
4	Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. Journal of Orthopaedic Science, 2000, 5, 600-604.	0.5	20
5	Characterization of the mouse Smad1 gene and its expression pattern in adult mouse tissues. Gene, 2000, 258, 43-53.	1.0	42
6	GROWTH FACTORS, RECEPTORS, AND MOLECULAR ALTERATIONS IN PANCREATIC CANCER. Medical Clinics of North America, 2000, 84, 697-705.	1.1	10
7	Growth factors in pancreatic health and disease. Pancreatology, 2001, 1, 343-355.	0.5	13
8	Pancreatic Cancer: Factors Regulating Tumor Development, Maintenance and Metastasis. Pancreatology, 2001, 1, 517-524.	0.5	42
9	Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood, 2001, 97, 516-522.	0.6	114
10	Expression of SMAD signal transduction molecules in the pancreas. Histochemistry and Cell Biology, 2001, 116, 263-267.	0.8	26
11	Growth factors and their receptors in pancreatic cancer. Teratogenesis, Carcinogenesis, and Mutagenesis, 2001, 21, 27-44.	0.8	76
12	Epigenetic Regulation of Human Bone Morphogenetic Protein 6 Gene Expression in Prostate Cancer. Journal of Bone and Mineral Research, 2001, 16, 487-496.	3.1	36
13	Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nature Genetics, 2001, 28, 184-187.	9.4	591
14	Overexpression of activin A in stage IV colorectal cancer. Gut, 2001, 49, 409-417.	6.1	87
15	Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Journal of Clinical Pathology, 2002, 55, 220-226.	2.1	149
16	Cerulein-Induced Acute Pancreatitis in the Rat is Significantly Ameliorated by Treatment With MEK1/2 Inhibitors U0126 and PD98059. Pancreas, 2002, 25, 251-259.	0.5	59
17	Gut reaction. Journal of Clinical Pathology, 2002, 55, 226-226.	2.1	2
18	Safety Profile for the Clinical Use of Bone Morphogenetic Proteins in the Spine. Spine, 2002, 27, S40-S48.	1.0	354

ATION RED

#	Article	IF	CITATIONS
19	BMP signalling regulates anteroposterior endoderm patterning in zebrafish. Mechanisms of Development, 2002, 118, 29-37.	1.7	146
20	The Stem Cell Factor–c-kit System and Mast Cells in Human Pancreatic Cancer. Laboratory Investigation, 2002, 82, 1481-1492.	1.7	77
22	Pathways for aberrant angiogenesis in pancreatic cancer. Molecular Cancer, 2003, 2, 8.	7.9	157
23	A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells. Biochemical and Biophysical Research Communications, 2003, 301, 108-112.	1.0	28
24	Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cellular and Molecular Life Sciences, 2003, 60, 1180-1199.	2.4	123
25	Distribution of Indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis. Journal of Endocrinology, 2003, 178, 467-478.	1.2	52
26	The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis, 2003, 24, 1445-1454.	1.3	157
27	Molecular Basis of Pancreatic Carcinogenesis: Which Concepts May Be Clinically Relevant?. , 0, , 351-358.		0
29	Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene, 2004, 23, 3737-3748.	2.6	68
30	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 2004, 59, 234-242.	1.2	98
31	Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. International Journal of Cancer, 2004, 110, 668-676.	2.3	91
32	Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology, 2004, 126, 111-121.	0.6	246
33	Effect of Recombinant Human Bone Morphogenetic Protein-2 in an Experimental Model of Spinal Fusion in a Radiated Area. Spine, 2005, 30, 2585-2592.	1.0	7
34	Influence of BMPs on the Formation of Osteoblastic Lesions in Metastatic Prostate Cancer. Journal of Bone and Mineral Research, 2005, 20, 2189-2199.	3.1	105
35	Bone morphogenetic proteins in melanoma: Angel or devil?. Cancer and Metastasis Reviews, 2005, 24, 251-263.	2.7	75
36	In vivo bone formation by human marrow stromal cells in biodegradable scaffolds that release dexamethasone and ascorbate-2-phosphate. Biochemical and Biophysical Research Communications, 2005, 332, 1053-1060.	1.0	83
37	Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin $\hat{I}^21$ into lipid rafts. Experimental Cell Research, 2006, 312, 3927-3938.	1.2	64
38	Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone, 2006, 38, 154-166.	1.4	138

#	Article	IF	CITATIONS
39	Response regarding the article "Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesionsâ€, by Feeley et al Bone, 2006, 39, 667.	1.4	0
40	Transforming growth factor-β pathway: Role in pancreas development and pancreatic disease. Cytokine and Growth Factor Reviews, 2006, 17, 107-119.	3.2	80
41	Correlation of glypican-1 expression with TGF-β, BMP, and activin receptors in pancreatic ductal adenocarcinoma. International Journal of Oncology, 2006, 29, 1139.	1.4	18
42	Hedgehog Signaling in the Normal and Diseased Pancreas. Pancreas, 2006, 32, 119-129.	0.5	60
43	Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration. Journal of Bone and Mineral Research, 2006, 21, 1571-1580.	3.1	107
44	A Polymorphism in a Conserved Posttranscriptional Regulatory Motif Alters Bone Morphogenetic Protein 2 (BMP2) RNA:Protein Interactions. Molecular Endocrinology, 2006, 20, 1574-1586.	3.7	28
45	BMP4 Regulates Pancreatic Progenitor Cell Expansion through Id2. Journal of Biological Chemistry, 2006, 281, 13574-13580.	1.6	91
46	Bone morphogenetic protein signaling and growth suppression in colon cancer. American Journal of Physiology - Renal Physiology, 2006, 291, G135-G145.	1.6	93
47	Pro-inflammatory Cytokine Tumor Necrosis Factor-α Induces Bone Morphogenetic Protein-2 in Chondrocytes via mRNA Stabilization and Transcriptional Up-regulation. Journal of Biological Chemistry, 2006, 281, 27229-27241.	1.6	74
48	Molecular Pathogenesis of Pancreatic Cancer: Advances and Challenges. Current Molecular Medicine, 2007, 7, 504-521.	0.6	61
49	Controlled release of recombinant human bone morphogenetic protein-7 in nanoscaffolds. Nanomedicine, 2007, 2, 385-390.	1.7	5
50	Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma1. Cancer Biomarkers, 2007, 3, 111-117.	0.8	38
51	Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin. International Journal of Oncology, 0, , .	1.4	9
52	Activation of growth factor receptors in pancreatic cancer. American Journal of Surgery, 2007, 194, S76-S83.	0.9	1
53	Modulation of Bone Morphogenetic Protein (BMP) 2 gene expression by Sp1 transcription factors. Gene, 2007, 392, 221-229.	1.0	20
54	Bone Morphogenetic Proteins and Their Receptors in the Eye. Experimental Biology and Medicine, 2007, 232, 979-992.	1.1	85
55	BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Molecular Cancer, 2007, 6, 83.	7.9	19
56	Antitumor activity of ALK1 in pancreatic carcinoma cells. International Journal of Cancer, 2007, 120, 1641-1651.	2.3	10

#	Article	IF	Citations
57	Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. Journal of Cellular Physiology, 2007, 213, 768-774.	2.0	86
58	Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene, 2007, 26, 4158-4170.	2.6	151
59	Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. British Journal of Cancer, 2007, 97, 1106-1115.	2.9	62
60	Noggin blocks invasive growth of murine B16â€F1 melanoma cells in the optic cup of the chick embryo. International Journal of Cancer, 2008, 122, 526-533.	2.3	20
61	Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by postâ€transcriptional mechanisms. Journal of Cellular Biochemistry, 2008, 104, 580-594.	1.2	47
62	The prognostic significance of BMP-6 signaling in prostate cancer. Modern Pathology, 2008, 21, 1436-1443.	2.9	39
63	Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 197-228.	1.8	544
64	Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut, 2008, 57, 1420-1430.	6.1	166
65	Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 208-219.	0.6	51
66	Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-Î <sup>2</sup> Type III Receptor. Journal of Biological Chemistry, 2008, 283, 7628-7637.	1.6	161
67	A COMPREHENSIVE REVIEW OF THE SAFETY PROFILE OF BONE MORPHOGENETIC PROTEIN IN SPINE SURGERY. Operative Neurosurgery, 2008, 62, ONS423-ONS431.	0.4	156
68	Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures. Biologics: Targets and Therapy, 2008, 2, 345.	3.0	17
69	The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer. Cancer Research and Treatment, 2008, 40, 127.	1.3	42
70	Expression and Functional Roles of Smad1 and BMPR-IB in Glioma Development. Cancer Investigation, 2009, 27, 734-740.	0.6	12
71	Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis, 2009, 30, 238-248.	1.3	108
72	rhBMP-2 as an Option for Reconstructing Mandibular Continuity Defects. Journal of Oral and Maxillofacial Surgery, 2009, 67, 2679-2684.	0.5	38
73	Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. Journal of Pathology, 2009, 218, 520-529.	2.1	81
74	BMP-2 signaling in ovarian cancer and its association with poor prognosis. Journal of Ovarian Research, 2009, 2, 4.	1.3	66

CITATION REPORT ARTICLE IF CITATIONS When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in 0.3 5 Cancer. Current Signal Transduction Therapy, 2009, 4, 174-195. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. 2.4 119 Cellular and Molecular Life Sciences, 2010, 67, 3535-3548. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate 1.2 33 with disease progression. Medical Oncology, 2010, 27, 1192-1199. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Research and Treatment, 2010, 124, 377-386. A conserved postâ€transcriptional BMP2 switch in lung cells. Journal of Cellular Biochemistry, 2010, 1.2 10 110, 509-521. Aberrant Signaling Pathways in Pancreatic Cancer., 2010, , 2783-2798. Role of RUNX3 in Bone Morphogenetic Protein Signaling in Colorectal Cancer. Cancer Research, 2010, 0.4 37 70, 4243-4252. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocrine-Related 1.6 Cancer, 2010, 17, R123-R139. Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell 0.7 23 carcinoma. International Journal of Oral and Maxillofacial Surgery, 2010, 39, 266-271. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine and Growth Factor Reviews, 3.2 2010, 21, 299-313. Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood 0.8 9 IgA nephropathy. Experimental and Therapeutic Medicine, 2011, 2, 337-341. Patterns of Bone Morphogenetic Protein-2 Expression in Smooth Muscle Tumors of the Uterine Corpus and Other Uterine Tissues. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 352-359. Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial 4.6 175 vein. Nature Cell Biology, 2011, 13, 686-692. Bone morphogenetic protein â^'4 and â^'5 in pancreatic cancer—Novel bidirectional players. Experimental Cell Research, 2011, 317, 2136-2146. 1.2 Ductal adenocarcinoma of the pancreas with psammomatous calcification: Report of a case with immunohistochemical study for bone morphogenetic protein. Pathology International, 2011, 61, 0.6 9 603-607. Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell lines. Laryngoscope, 2011, 121, 23 1876-1880. BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer 1.581 Biology and Therapy, 2011, 11, 457-463.

92	Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer Cells. Clinical Cancer Research, 2011, 17, 2744-2756.	3.2	69
----	---	-----	----

#

75

77

79

81

83

84

85

86

87

89

#	Article	IF	CITATIONS
93	Spinal Reconstruction with Pedicle Screw-Based Instrumentation and rhBMP-2 in Patients with Neurofibromatosis and Severe Dural Ectasia and Spinal Deformity. Journal of Bone and Joint Surgery - Series A, 2011, 93, e86.	1.4	15
94	The Smad family and its role in pancreatic cancer. Indian Journal of Cancer, 2011, 48, 351.	0.2	39
95	Regulators of epithelial mesenchymal transition in pancreatic cancer. Frontiers in Physiology, 2012, 3, 254.	1.3	16
96	Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future. Current Medicinal Chemistry, 2012, 19, 3664-3678.	1.2	3
97	Bone Morphogenetic Protein in Spine Surgery: Current and Future Uses. Journal of the American Academy of Orthopaedic Surgeons, The, 2012, 20, 547-552.	1.1	74
98	BMPâ€2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. International Journal of Cancer, 2012, 131, 1941-1950.	2.3	26
99	Stool DNA testing for the detection of pancreatic cancer. Cancer, 2012, 118, 2623-2631.	2.0	110
100	BMP signaling in vascular diseases. FEBS Letters, 2012, 586, 1993-2002.	1.3	236
101	Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochemical Pharmacology, 2012, 83, 452-461.	2.0	23
102	Tumor-stromal interactions in pancreatic cancer. Pancreatology, 2013, 13, 1-7.	0.5	190
103	Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. British Journal of Cancer, 2013, 109, 1805-1812.	2.9	24
104	Risk of Cancer After Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rh-BMP-2). Spine, 2013, 38, 1862-1868.	1.0	63
105	Fibroblast Growth Factor-2 and Bone Morphogenetic Protein-2 Have a Synergistic Stimulatory Effect on Bone Formation in Cell Cultures From Elderly Mouse and Human Bone. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 1170-1180.	1.7	42
106	Cancer After Spinal Fusion. Neurosurgery, 2013, 73, 440-449.	0.6	70
107	Bone formation induced by BMP-2 in human osteosarcoma cells. International Journal of Oncology, 2013, 43, 1095-1102.	1.4	32
108	Severe Mandibular Atrophy Treated With a Subperiosteal Implant and Simultaneous Graft With rhBMP-2 and Mineralized Allograft: A Case Report. Journal of Oral Implantology, 2014, 40, 707-713.	0.4	7
109	BMP-2 Expression Correlates with Local Failure in Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2014, 150, 245-250.	1.1	24
110	Recombinant Human Bone Morphogenetic Protein-2 in Spine Surgery. JBJS Reviews, 2014, 2, .	0.8	8

CITATION REPORT
-----------------

#	Article	IF	CITATIONS
111	Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling. Journal of Translational Medicine, 2014, 12, 309.	1.8	9
112	Effect of grafting BMP2-derived peptide to nanoparticles on osteogenic and vasculogenic expression of stromal cells. Journal of Tissue Engineering and Regenerative Medicine, 2014, 8, 15-28.	1.3	21
113	Biomaterial Scaffolds for Treating Osteoporotic Bone. Current Osteoporosis Reports, 2014, 12, 48-54.	1.5	56
114	Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine Journal, 2014, 14, 552-559.	0.6	355
115	Association Between BMP-2 and Carcinogenicity. Spine, 2015, 40, 1862-1871.	1.0	59
116	BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1013-1024.	1.2	37
117	A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis. Journal of Neurosurgery: Spine, 2015, 23, 86-93.	0.9	57
118	Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology, 2015, 15, 156-161.	0.5	19
119	A glass polyalkenoate cement carrier for bone morphogenetic proteins. Journal of Materials Science: Materials in Medicine, 2015, 26, 151.	1.7	1
120	Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2. Biochemical and Biophysical Research Communications, 2015, 466, 167-172.	1.0	22
121	Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma. Acta Biochimica Et Biophysica Sinica, 2015, 47, 557-563.	0.9	26
122	Bone morphogenetic proteinâ€⊋ expression in an intraductal papillary mucinous neoplasm with marked ossification: A case report. Pathology International, 2016, 66, 343-347.	0.6	2
123	Inhibitory effect of bone morphogenetic protein-2 on the proliferation of giant cell tumor of bone stromal cells in vitro. Experimental and Therapeutic Medicine, 2016, 11, 309-314.	0.8	0
124	Bone morphogenetic protein signaling in musculoskeletal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2061-2072.	1.2	20
125	BMP 2 usage in posterior lumbar fusion in degenerative conditions. Seminars in Spine Surgery, 2016, 28, 239-244.	0.1	2
126	A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Engineering - Part B: Reviews, 2016, 22, 284-297.	2.5	741
127	Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy. Cytokine and Growth Factor Reviews, 2017, 34, 73-91.	3.2	28
128	Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Seminars in Cancer Biology, 2017, 44, 43-59.	4.3	89

#	Article	IF	CITATIONS
129	Bone morphogenetic protein (BMP-2) usage and cancer correlation: An analysis of 10,416 spine fusion patients from a multi-center spine registry. Journal of Clinical Neuroscience, 2017, 43, 214-219.	0.8	10
130	Systematic single-cell analysis provides new insights into heterogeneity and plasticity of the pancreas. Molecular Metabolism, 2017, 6, 974-990.	3.0	95
131	RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene, 2017, 36, 1297-1308.	2.6	59
132	Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Oncogene, 2018, 37, 3672-3685.	2.6	13
133	BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model. OncoTargets and Therapy, 2018, Volume 11, 7543-7553.	1.0	10
134	Osteogenic Enhancement Between Icariin and Bone Morphogenetic Protein 2: A Potential Osteogenic Compound for Bone Tissue Engineering. Frontiers in Pharmacology, 2019, 10, 201.	1.6	18
135	Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein. Cell Communication and Signaling, 2019, 17, 150.	2.7	6
136	The Epstein-Barr Virus-Encoded EBNA1 Protein Activates the Bone Morphogenic Protein (BMP) Signalling Pathway to Promote Carcinoma Cell Migration. Pathogens, 2020, 9, 594.	1.2	5
137	Extracellular BMP Antagonists, Multifaceted Orchestrators in the Tumor and Its Microenvironment. International Journal of Molecular Sciences, 2020, 21, 3888.	1.8	16
138	Function of BMP4 in the Formation of Vasculogenic Mimicry in Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 2560-2571.	1.2	15
139	Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer. Oncogene, 2020, 39, 2453-2466.	2.6	18
140	Bone morphogenetic protein induces bone invasion of melanoma by epithelial–mesenchymal transition via the Smad1/5 signaling pathway. Laboratory Investigation, 2021, 101, 1475-1483.	1.7	9
141	Aberrant Transforming Growth Factor- $\hat{l}^2$ Signaling in Human Pancreatic Cancer: Translational Implications. , 2008, , 523-535.		1
142	Bone morphogenetic proteins and cancer. , 2004, , 267-292.		2
143	Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population. International Journal of Spine Surgery, 2018, 12, 260-268.	0.7	8
145	Bone Morphogenetic Protein in Spine Surgery: Current and Future Uses. Journal of the American Academy of Orthopaedic Surgeons, The, 2012, 20, 547-552.	1.1	55
146	BMPs and their clinical potentials. BMB Reports, 2011, 44, 619-634.	1.1	76
147	Opportunities in Spinal Applications. , 2004, , 315-329.		Ο

# 148	ARTICLE Transforming Growth Factor-Î <sup>2</sup> Signaling in Pancreas Development and Pancreatic Disease. , 2008, , 3-1	IF 9.	CITATIONS
149	Bone Morphogenic Proteins and Angiogenesis in Developing Tumors. , 2008, , 373-381.		0
150	Biologics for Adult Lumbar Scoliosis. , 2017, , 107-121.		0
152	The Role of SMAD4 Inactivation in Epithelial–Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link?. Cancers, 2022, 14, 973.	1.7	6
153	DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences, 2022, 23, 2117.	1.8	8
154	Bone Morphogenic Proteins Are Overexpressed in Malignant Melanoma and Promote Cell Invasion and Migration. Cancer Research, 2005, 65, 448-456.	0.4	204
155	Bone Morphogenetic Protein-2 Stimulates Angiogenesis in Developing Tumors. Molecular Cancer Research, 2004, 2, 141-149.	1.5	239